文献速递造血干细胞移植与细胞治疗白血病

异基因造血细胞移植后巨细胞病毒再激活与急性淋巴细胞白血病复发风险降低相关

CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2023-01-01

这项全国性回顾性研究纳入首次或第二次完全缓解的急性髓系白血病和急性淋巴细胞白血病患者,均接受首次异基因造血细胞移植并采用抢先策略处理巨细胞病毒再激活。以第65天为界标点分析显示,巨细胞病毒再激活与急性髓系白血病(HR 0.81)和急性淋巴细胞白血病(HR 0.81)复发发生率降低相关,且该保护效应独立于急性移植物抗宿主病。

要点

  • 巨细胞病毒再激活与急性髓系白血病复发风险降低相关(HR 0.81,95%CI 0.69-0.95,P=.009)。
  • 巨细胞病毒再激活与急性淋巴细胞白血病复发风险降低相关(HR 0.81,95%CI 0.66-0.99,P=.045)。
  • 巨细胞病毒再激活对复发的保护效应独立于急性移植物抗宿主病。

核心结论

  • 异基因造血细胞移植后巨细胞病毒再激活与急性髓系白血病和急性淋巴细胞白血病复发发生率降低相关,且该保护效应独立于急性移植物抗宿主病。

研究设计与样本

  • 全国性回顾性研究,纳入首次或第二次完全缓解、接受首次异基因造血细胞移植并采用抢先策略处理巨细胞病毒再激活的急性髓系白血病和急性淋巴细胞白血病患者。
  • 因90%的巨细胞病毒再激活发生在第64天前、90%的2至4级急性移植物抗宿主病发生在第58天前,设第65天为界标点。
  • 界标分析纳入无复发生存至少65天的3793例急性髓系白血病患者和2213例急性淋巴细胞白血病患者。

主要发现

  • 多因素分析显示,巨细胞病毒再激活与急性髓系白血病复发发生率降低相关(HR 0.81,95%CI 0.69-0.95,P=.009)。
  • 多因素分析显示,巨细胞病毒再激活与急性淋巴细胞白血病复发发生率降低相关(HR 0.81,95%CI 0.66-0.99,P=.045)。
  • 将巨细胞病毒再激活作为时间依赖协变量分析时,上述结果得到确认。
  • 研究提示巨细胞病毒再激活对复发的保护效应独立于急性移植物抗宿主病。
  • 急性髓系白血病和急性淋巴细胞白血病合并的事后亚组分析显示,巨细胞病毒再激活具有轻度抗白血病效应且无效应修饰,与其对非复发死亡的影响不同。

临床怎么用

  • 原文结论指出,这些发现可能对异基因造血细胞移植后巨细胞病毒预防策略具有重要启示。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytomegalovirus reactivation (CMVR) after allogeneic hematopoietic cell transplantation (HCT) is a frequent complication related to survival outcomes; however, its impact on relapse remains unclear, especially in acute lymphoblastic leukemia (ALL). In this nationwide retrospective study, we included patients with acute myeloid leukemia (AML) and ALL in the first or second complete remission who underwent their first HCT using a pre-emptive strategy for CMVR. Because 90% of cases with CMVR had occurred by day 64 and 90% of cases with grades 2 to 4 acute graft-versus-host disease (GVHD) had occurred by day 58, a landmark point was set at day 65. In landmark analyses, 3793 patients with AML and 2213 patients with ALL who survived without relapse for at least 65 days were analyzed. Multivariate analyses showed that CMVR was associated with a lower incidence of relapse in both AML (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.69-0.95; P = .009) and ALL (HR, 0.81; 95% CI, 0.66-0.99; P = .045). These findings were confirmed when CMVR was used as the time-dependent covariate. Moreover, our study suggests that the protective effect of CMVR on relapse was independent of acute GVHD. A post-hoc subgroup analysis of combined AML and ALL showed that CMVR had a mild antileukemia effect without effect modification, in contrast to the impact of CMVR on NRM. Our findings may provide important implications for strategies used for CMV prophylaxis after HCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Akahoshi Y, Nakasone H, Takenaka K, et al. CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia. Blood Adv. 2023. PMID: 36661335. doi:10.1182/bloodadvances.2022009376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。